Patricia C. Hirano - Jun 24, 2025 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Senior Vice President, Regulatory Affairs
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Stock symbol
SLNO
Transactions as of
Jun 24, 2025
Transactions value $
-$10,640
Form type
4
Date filed
6/26/2025, 06:04 PM
Previous filing
Apr 2, 2025
Next filing
Jul 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hirano Patricia C Officer title: Senior Vice President, Regulatory Affairs 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY /s/ Anish Bhatnagar, Attorney-in-Fact 2025-06-26 0001766042

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Options Exercise $11.8K +266 +1.56% $44.25 17.3K Jun 24, 2025 Direct F1, F2, F3
transaction SLNO Common Stock Sale -$22.4K -266 -1.54% $84.25 17K Jun 24, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -266 -100% $0.00 0 Jun 24, 2025 Common Stock 266 $44.25 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person September 13, 2024
F2 Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3 The number of shares beneficially owned has been decreased by 10,000 shares pursuant to an internal review of the Reporting Person's holdings.
F4 All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Remarks:

Officer title: Senior Vice President, Regulatory Affairs